Target Information

Target General Infomation
Target ID
T09058
Former ID
TTDR00714
Target Name
5T4 ONCOFETAL antigen
Gene Name
TPBG
Synonyms
Trophoblast glycoprotein; TPBG
Target Type
Clinical Trial
Disease Breast cancer [ICD9: 174, 175; ICD10: C50]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Hormone refractory prostate cancer [ICD9: 140-229, 185; ICD10: C61]
Non-small cell lung cancer [ICD10: C33-C34]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Function
May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a- dependent LRP6 internalization.
BioChemical Class
Transmembrane protein
UniProt ID
Q13641
Sequence
MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSPTSSASSFSSSAPFLASAVSAQPPLPD
QCPALCECSEAARTVKCVNRNLTEVPTDLPAYVRNLFLTGNQLAVLPAGAFARRPPLAEL
AALNLSGSRLDEVRAGAFEHLPSLRQLDLSHNPLADLSPFAFSGSNASVSAPSPLVELIL
NHIVPPEDERQNRSFEGMVVAALLAGRALQGLRRLELASNHFLYLPRDVLAQLPSLRHLD
LSNNSLVSLTYVSFRNLTHLESLHLEDNALKVLHNGTLAELQGLPHIRVFLDNNPWVCDC
HMADMVTWLKETEVVQGKDRLTCAYPEKMRNRVLLELNSADLDCDPILPPSLQTSYVFLG
IVLALIGAIFLLVLYLNRKGIKKWMHNIRDACRDHMEGYHYRYEINADPRLTNLSSNSDV
Drugs and Mode of Action
Drug(s) TroVax Drug Info Phase 3 Hormone refractory prostate cancer [521911]
Naptumomab estafenatox Drug Info Phase 2/3 Solid tumours [521947]
CV-9201 Drug Info Phase 1/2 Non-small cell lung cancer [522696]
PF-06263507 Drug Info Phase 1 Cancer [524349]
Anatumomab mafenatox Drug Info Terminated Breast cancer [528658]
Immunomodulator Naptumomab estafenatox Drug Info [532633]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
References
Ref 521911ClinicalTrials.gov (NCT00397345) TroVax Renal Immunotherapy Survival Trial. U.S. National Institutes of Health.
Ref 521947ClinicalTrials.gov (NCT00420888) ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma. U.S. National Institutes of Health.
Ref 522696ClinicalTrials.gov (NCT00923312) Trial of an RNActive-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC). U.S. National Institutes of Health.
Ref 524349ClinicalTrials.gov (NCT01891669) A Study Of PF-06263507 In Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 528658A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74. Epub 2007 Feb 6.
Ref 528658A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74. Epub 2007 Feb 6.
Ref 531184Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47.
Ref 532633Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
Ref 550441National Cancer Institute Drug Dictionary (drug id 648549).
Ref 550498National Cancer Institute Drug Dictionary (drug id 751006).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.